BioNano Genomics (NASDAQ:BNGO) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
This table compares BioNano Genomics and Quanterix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for BioNano Genomics and Quanterix, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioNano Genomics presently has a consensus target price of $12.00, indicating a potential upside of 166.67%. Quanterix has a consensus target price of $26.50, indicating a potential upside of 23.26%. Given BioNano Genomics’ higher possible upside, equities analysts plainly believe BioNano Genomics is more favorable than Quanterix.
Valuation and Earnings
This table compares BioNano Genomics and Quanterix’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioNano Genomics||$9.50 million||4.75||-$23.36 million||N/A||N/A|
|Quanterix||$22.87 million||20.87||-$27.01 million||($8.30)||-2.59|
BioNano Genomics has higher earnings, but lower revenue than Quanterix.
Institutional & Insider Ownership
80.3% of BioNano Genomics shares are owned by institutional investors. Comparatively, 49.6% of Quanterix shares are owned by institutional investors. 31.6% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioNano Genomics beats Quanterix on 6 of the 9 factors compared between the two stocks.
BioNano Genomics Company Profile
BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.